383 related articles for article (PubMed ID: 19484790)
21. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.
Maluta S; Dall'oglio S; Nadalini L
Int J Hyperthermia; 2010; 26(8):765-74. PubMed ID: 21043571
[TBL] [Abstract][Full Text] [Related]
22. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
23. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
Milecki P
Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
[TBL] [Abstract][Full Text] [Related]
24. External-beam radiotherapy for localized or locally advanced prostate cancer in Japan: a multi-institutional outcome analysis.
Nakamura K; Mizowaki T; Imada H; Karasawa K; Uno T; Onishi H; Nihei K; Sasaki S; Ogura M; Akimoto T
Jpn J Clin Oncol; 2008 Mar; 38(3):200-4. PubMed ID: 18304950
[TBL] [Abstract][Full Text] [Related]
25. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
Akaza H; Hirao Y; Labrie F; Soloway MS
Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
[TBL] [Abstract][Full Text] [Related]
26. New trends in prostatic cancer research. Hormone therapy in localized carcinoma of the prostate.
Perez CA
Rays; 2000; 25(3):345-51. PubMed ID: 11367900
[TBL] [Abstract][Full Text] [Related]
27. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
[TBL] [Abstract][Full Text] [Related]
28. Combination hormonal therapy: a reassessment within advanced prostate cancer.
Moul JW; Chodak G
Prostate Cancer Prostatic Dis; 2004 Sep; 7 Suppl 1():S2-7. PubMed ID: 15365575
[TBL] [Abstract][Full Text] [Related]
29. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
Iversen P; Roder MA
Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for localized, high-risk prostate cancer.
Narayan S; Smith DC; Sandler HM
Semin Radiat Oncol; 2003 Apr; 13(2):152-7. PubMed ID: 12728444
[TBL] [Abstract][Full Text] [Related]
31. Radiation therapy combined with hormone therapy for prostate cancer.
Lee AK
Semin Radiat Oncol; 2006 Jan; 16(1):20-8. PubMed ID: 16378903
[TBL] [Abstract][Full Text] [Related]
32. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
Bolla M; Fourneret P; Descotes JL
Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
[TBL] [Abstract][Full Text] [Related]
33. Combined hormone therapy and radiation therapy for locally advanced prostate cancer.
Bolla M; Laramas M;
Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e30-4. PubMed ID: 21144766
[TBL] [Abstract][Full Text] [Related]
34. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
[TBL] [Abstract][Full Text] [Related]
35. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.
Cuppone F; Bria E; Giannarelli D; Vaccaro V; Milella M; Nisticò C; Ruggeri EM; Sperduti I; Bracarda S; Pinnarò P; Lanzetta G; Muti P; Cognetti F; Carlini P
BMC Cancer; 2010 Dec; 10():675. PubMed ID: 21143897
[TBL] [Abstract][Full Text] [Related]
36. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
[TBL] [Abstract][Full Text] [Related]
37. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
Denham JW; Steigler A; Wilcox C; Lamb DS; Joseph D; Atkinson C; Tai KH; Spry NA; Gleeson PS; D'Este C
Cancer; 2009 Oct; 115(19):4477-87. PubMed ID: 19691097
[TBL] [Abstract][Full Text] [Related]
38. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
39. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
40. Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique.
Jani AB
Cancer Invest; 2006; 24(3):318-27. PubMed ID: 16809161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
